Edwards Lifesciences Corporation (EW) Welcomes Newly Updated ESC/EACTS Guidelines for Severe Aortic Stenosis (AS)

Group 1 - Edwards Lifesciences Corporation (EW) has positively responded to the updated ESC/EACTS guidelines for severe aortic stenosis (AS), which recommend earlier treatment for asymptomatic patients and lower the TAVR age threshold to 70 [2][4] - The company is the only one with an approved TAVR indication for asymptomatic severe AS in the U.S. and Europe, emphasizing its critical EARLY TAVR trial and the CE Mark for its SAPIEN 3 platform [3][4] - Data from the TRISCEND II study presented at the ESC Congress indicates that the EVOQUE tricuspid valve replacement significantly reduced heart failure hospitalizations at 18 months, reinforcing the company's leadership in structural heart innovation [4] Group 2 - Edwards Lifesciences specializes in structural heart therapies, pioneering innovations in TAVR, mitral, and tricuspid procedures to improve patient outcomes and expand access globally [5]